nodes	percent_of_prediction	percent_of_DWPC	metapath
Zalcitabine—Decitabine—Cladribine—multiple sclerosis	0.358	1	CrCrCtD
Zalcitabine—DCK—Cladribine—multiple sclerosis	0.219	0.453	CbGbCtD
Zalcitabine—CYP3A43—Dexamethasone—multiple sclerosis	0.0896	0.185	CbGbCtD
Zalcitabine—SLC22A7—Methotrexate—multiple sclerosis	0.027	0.0558	CbGbCtD
Zalcitabine—CYP2D6—Fingolimod—multiple sclerosis	0.0246	0.0509	CbGbCtD
Zalcitabine—CYP3A4—Fingolimod—multiple sclerosis	0.0157	0.0323	CbGbCtD
Zalcitabine—CYP3A7—Dexamethasone—multiple sclerosis	0.0131	0.0269	CbGbCtD
Zalcitabine—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0131	0.0269	CbGbCtD
Zalcitabine—SLC22A6—Methotrexate—multiple sclerosis	0.0115	0.0237	CbGbCtD
Zalcitabine—CYP3A4—Methylprednisolone—multiple sclerosis	0.0101	0.0208	CbGbCtD
Zalcitabine—CYP3A5—Dexamethasone—multiple sclerosis	0.00979	0.0202	CbGbCtD
Zalcitabine—CYP3A4—Triamcinolone—multiple sclerosis	0.00765	0.0158	CbGbCtD
Zalcitabine—CYP3A4—Mitoxantrone—multiple sclerosis	0.00737	0.0152	CbGbCtD
Zalcitabine—CYP2C9—Dexamethasone—multiple sclerosis	0.00657	0.0136	CbGbCtD
Zalcitabine—CYP3A4—Betamethasone—multiple sclerosis	0.00657	0.0136	CbGbCtD
Zalcitabine—CYP3A4—Prednisolone—multiple sclerosis	0.00648	0.0134	CbGbCtD
Zalcitabine—CYP3A4—Prednisone—multiple sclerosis	0.00612	0.0126	CbGbCtD
Zalcitabine—CYP2D6—Dexamethasone—multiple sclerosis	0.00601	0.0124	CbGbCtD
Zalcitabine—CYP3A4—Dexamethasone—multiple sclerosis	0.00382	0.00788	CbGbCtD
Zalcitabine—Gemcitabine—RRM1—multiple sclerosis	0.00272	1	CrCbGaD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.0012	0.0457	CbGpPWpGaD
Zalcitabine—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000814	0.031	CbGpPWpGaD
Zalcitabine—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000814	0.031	CbGpPWpGaD
Zalcitabine—CYP3A43—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000803	0.0306	CbGpPWpGaD
Zalcitabine—CYP3A43—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000803	0.0306	CbGpPWpGaD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.000684	0.026	CbGpPWpGaD
Zalcitabine—CYP3A43—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00066	0.0251	CbGpPWpGaD
Zalcitabine—CYP3A43—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00066	0.0251	CbGpPWpGaD
Zalcitabine—DCK—Nucleotide metabolism—RRM1—multiple sclerosis	0.000508	0.0193	CbGpPWpGaD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000471	0.0179	CbGpPWpGaD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—RRM1—multiple sclerosis	0.000465	0.0177	CbGpPWpGaD
Zalcitabine—SLC29A2—Transport of vitamins, nucleosides, and related molecules—ALB—multiple sclerosis	0.000419	0.0159	CbGpPWpGaD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000357	0.0136	CbGpPWpGaD
Zalcitabine—CYP3A43—Biological oxidations—CYP24A1—multiple sclerosis	0.00035	0.0133	CbGpPWpGaD
Zalcitabine—CYP3A43—Biological oxidations—CYP27B1—multiple sclerosis	0.00035	0.0133	CbGpPWpGaD
Zalcitabine—CYP3A43—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000346	0.0132	CbGpPWpGaD
Zalcitabine—CYP3A43—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000346	0.0132	CbGpPWpGaD
Zalcitabine—CYP3A5—Irinotecan Pathway—BCHE—multiple sclerosis	0.00033	0.0126	CbGpPWpGaD
Zalcitabine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000328	0.0125	CbGpPWpGaD
Zalcitabine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000328	0.0125	CbGpPWpGaD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000327	0.0124	CbGpPWpGaD
Zalcitabine—CYP3A7—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000323	0.0123	CbGpPWpGaD
Zalcitabine—CYP3A7—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000323	0.0123	CbGpPWpGaD
Zalcitabine—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—multiple sclerosis	0.000311	0.0118	CbGpPWpGaD
Zalcitabine—SLC29A1—Transport of vitamins, nucleosides, and related molecules—ALB—multiple sclerosis	0.00029	0.011	CbGpPWpGaD
Zalcitabine—CYP3A7—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000266	0.0101	CbGpPWpGaD
Zalcitabine—CYP3A7—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000266	0.0101	CbGpPWpGaD
Zalcitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000263	0.01	CbGpPWpGaD
Zalcitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000263	0.01	CbGpPWpGaD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.00025	0.0095	CbGpPWpGaD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000248	0.00943	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.00024	0.00912	CbGpPWpGaD
Zalcitabine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000237	0.00902	CbGpPWpGaD
Zalcitabine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000237	0.00902	CbGpPWpGaD
Zalcitabine—CYP3A5—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000234	0.0089	CbGpPWpGaD
Zalcitabine—CYP3A5—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000234	0.0089	CbGpPWpGaD
Zalcitabine—DCK—Desoximetasone—Methylprednisolone—multiple sclerosis	0.000225	0.0885	CbGdCrCtD
Zalcitabine—DCK—Desoximetasone—Dexamethasone—multiple sclerosis	0.000221	0.0871	CbGdCrCtD
Zalcitabine—DCK—Desoximetasone—Betamethasone—multiple sclerosis	0.000221	0.0871	CbGdCrCtD
Zalcitabine—DCK—Diflorasone—Methylprednisolone—multiple sclerosis	0.000218	0.0859	CbGdCrCtD
Zalcitabine—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—multiple sclerosis	0.000218	0.00829	CbGpPWpGaD
Zalcitabine—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—multiple sclerosis	0.000217	0.00826	CbGpPWpGaD
Zalcitabine—DCK—Desoximetasone—Triamcinolone—multiple sclerosis	0.000216	0.0851	CbGdCrCtD
Zalcitabine—DCK—Diflorasone—Betamethasone—multiple sclerosis	0.000215	0.0845	CbGdCrCtD
Zalcitabine—DCK—Diflorasone—Dexamethasone—multiple sclerosis	0.000215	0.0845	CbGdCrCtD
Zalcitabine—DCK—Diflorasone—Triamcinolone—multiple sclerosis	0.00021	0.0826	CbGdCrCtD
Zalcitabine—DCK—Desoximetasone—Prednisone—multiple sclerosis	0.000205	0.0808	CbGdCrCtD
Zalcitabine—DCK—Desoximetasone—Prednisolone—multiple sclerosis	0.0002	0.0788	CbGdCrCtD
Zalcitabine—DCK—Diflorasone—Prednisone—multiple sclerosis	0.000199	0.0784	CbGdCrCtD
Zalcitabine—DCK—Diflorasone—Prednisolone—multiple sclerosis	0.000194	0.0765	CbGdCrCtD
Zalcitabine—CYP3A5—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000192	0.00731	CbGpPWpGaD
Zalcitabine—CYP3A5—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000192	0.00731	CbGpPWpGaD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000186	0.00709	CbGpPWpGaD
Zalcitabine—CYP3A43—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000183	0.00697	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000182	0.00691	CbGpPWpGaD
Zalcitabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000173	0.0066	CbGpPWpGaD
Zalcitabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000173	0.0066	CbGpPWpGaD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000173	0.00659	CbGpPWpGaD
Zalcitabine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000168	0.00641	CbGpPWpGaD
Zalcitabine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000168	0.00641	CbGpPWpGaD
Zalcitabine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000167	0.00636	CbGpPWpGaD
Zalcitabine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000167	0.00636	CbGpPWpGaD
Zalcitabine—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000166	0.00633	CbGpPWpGaD
Zalcitabine—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000166	0.00633	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000166	0.00632	CbGpPWpGaD
Zalcitabine—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000165	0.00627	CbGpPWpGaD
Zalcitabine—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000165	0.00627	CbGpPWpGaD
Zalcitabine—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000154	0.00585	CbGpPWpGaD
Zalcitabine—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—multiple sclerosis	0.000152	0.00579	CbGpPWpGaD
Zalcitabine—CYP3A43—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000148	0.00565	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000144	0.00546	CbGpPWpGaD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000141	0.00537	CbGpPWpGaD
Zalcitabine—CYP3A7—Biological oxidations—CYP27B1—multiple sclerosis	0.000141	0.00537	CbGpPWpGaD
Zalcitabine—CYP3A7—Biological oxidations—CYP24A1—multiple sclerosis	0.000141	0.00537	CbGpPWpGaD
Zalcitabine—CYP3A7—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000139	0.0053	CbGpPWpGaD
Zalcitabine—CYP3A7—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000139	0.0053	CbGpPWpGaD
Zalcitabine—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000137	0.0052	CbGpPWpGaD
Zalcitabine—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000137	0.0052	CbGpPWpGaD
Zalcitabine—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000135	0.00515	CbGpPWpGaD
Zalcitabine—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000135	0.00515	CbGpPWpGaD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000131	0.00497	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000127	0.00483	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000126	0.00479	CbGpPWpGaD
Zalcitabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00011	0.00419	CbGpPWpGaD
Zalcitabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00011	0.00419	CbGpPWpGaD
Zalcitabine—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000109	0.00414	CbGpPWpGaD
Zalcitabine—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000109	0.00414	CbGpPWpGaD
Zalcitabine—CYP3A5—Biological oxidations—CYP24A1—multiple sclerosis	0.000102	0.00388	CbGpPWpGaD
Zalcitabine—CYP3A5—Biological oxidations—CYP27B1—multiple sclerosis	0.000102	0.00388	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000101	0.00383	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000101	0.00383	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	9.95e-05	0.00379	CbGpPWpGaD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	9.9e-05	0.00377	CbGpPWpGaD
Zalcitabine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	9.88e-05	0.00376	CbGpPWpGaD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	9.86e-05	0.00375	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	9.46e-05	0.0036	CbGpPWpGaD
Zalcitabine—Shock—Prednisolone—multiple sclerosis	9.19e-05	0.000728	CcSEcCtD
Zalcitabine—Cough—Triamcinolone—multiple sclerosis	9.18e-05	0.000728	CcSEcCtD
Zalcitabine—Convulsion—Triamcinolone—multiple sclerosis	9.12e-05	0.000723	CcSEcCtD
Zalcitabine—Tachycardia—Prednisolone—multiple sclerosis	9.11e-05	0.000722	CcSEcCtD
Zalcitabine—Photosensitivity reaction—Methotrexate—multiple sclerosis	9.1e-05	0.000721	CcSEcCtD
Zalcitabine—Convulsion—Methylprednisolone—multiple sclerosis	9.1e-05	0.000721	CcSEcCtD
Zalcitabine—Hypertension—Triamcinolone—multiple sclerosis	9.08e-05	0.00072	CcSEcCtD
Zalcitabine—Hypertension—Methylprednisolone—multiple sclerosis	9.06e-05	0.000718	CcSEcCtD
Zalcitabine—Urticaria—Mitoxantrone—multiple sclerosis	9.04e-05	0.000717	CcSEcCtD
Zalcitabine—Hyperhidrosis—Prednisolone—multiple sclerosis	9.03e-05	0.000716	CcSEcCtD
Zalcitabine—Abdominal pain—Mitoxantrone—multiple sclerosis	9e-05	0.000713	CcSEcCtD
Zalcitabine—Body temperature increased—Mitoxantrone—multiple sclerosis	9e-05	0.000713	CcSEcCtD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—ALB—multiple sclerosis	8.99e-05	0.00342	CbGpPWpGaD
Zalcitabine—Myalgia—Triamcinolone—multiple sclerosis	8.96e-05	0.00071	CcSEcCtD
Zalcitabine—Vomiting—Azathioprine—multiple sclerosis	8.95e-05	0.00071	CcSEcCtD
Zalcitabine—Arthralgia—Methylprednisolone—multiple sclerosis	8.94e-05	0.000708	CcSEcCtD
Zalcitabine—Myalgia—Methylprednisolone—multiple sclerosis	8.94e-05	0.000708	CcSEcCtD
Zalcitabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	8.93e-05	0.0034	CbGpPWpGaD
Zalcitabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	8.93e-05	0.0034	CbGpPWpGaD
Zalcitabine—Eye disorder—Prednisone—multiple sclerosis	8.93e-05	0.000707	CcSEcCtD
Zalcitabine—Anxiety—Methylprednisolone—multiple sclerosis	8.91e-05	0.000706	CcSEcCtD
Zalcitabine—Rash—Azathioprine—multiple sclerosis	8.88e-05	0.000704	CcSEcCtD
Zalcitabine—Dermatitis—Azathioprine—multiple sclerosis	8.87e-05	0.000703	CcSEcCtD
Zalcitabine—Depression—Methotrexate—multiple sclerosis	8.87e-05	0.000703	CcSEcCtD
Zalcitabine—Flushing—Prednisone—multiple sclerosis	8.86e-05	0.000703	CcSEcCtD
Zalcitabine—Ill-defined disorder—Betamethasone—multiple sclerosis	8.86e-05	0.000702	CcSEcCtD
Zalcitabine—Ill-defined disorder—Dexamethasone—multiple sclerosis	8.86e-05	0.000702	CcSEcCtD
Zalcitabine—Discomfort—Triamcinolone—multiple sclerosis	8.85e-05	0.000702	CcSEcCtD
Zalcitabine—Discomfort—Methylprednisolone—multiple sclerosis	8.83e-05	0.0007	CcSEcCtD
Zalcitabine—Headache—Azathioprine—multiple sclerosis	8.82e-05	0.000699	CcSEcCtD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	8.79e-05	0.00335	CbGpPWpGaD
Zalcitabine—Dry mouth—Triamcinolone—multiple sclerosis	8.76e-05	0.000694	CcSEcCtD
Zalcitabine—Confusional state—Methylprednisolone—multiple sclerosis	8.64e-05	0.000685	CcSEcCtD
Zalcitabine—DCK—Metabolism—SRM—multiple sclerosis	8.63e-05	0.00329	CbGpPWpGaD
Zalcitabine—Malaise—Dexamethasone—multiple sclerosis	8.61e-05	0.000682	CcSEcCtD
Zalcitabine—Malaise—Betamethasone—multiple sclerosis	8.61e-05	0.000682	CcSEcCtD
Zalcitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	8.61e-05	0.00328	CbGpPWpGaD
Zalcitabine—Oedema—Triamcinolone—multiple sclerosis	8.59e-05	0.000681	CcSEcCtD
Zalcitabine—Vertigo—Betamethasone—multiple sclerosis	8.58e-05	0.00068	CcSEcCtD
Zalcitabine—Vertigo—Dexamethasone—multiple sclerosis	8.58e-05	0.00068	CcSEcCtD
Zalcitabine—Syncope—Betamethasone—multiple sclerosis	8.56e-05	0.000679	CcSEcCtD
Zalcitabine—Syncope—Dexamethasone—multiple sclerosis	8.56e-05	0.000679	CcSEcCtD
Zalcitabine—Arrhythmia—Prednisone—multiple sclerosis	8.53e-05	0.000676	CcSEcCtD
Zalcitabine—Infection—Triamcinolone—multiple sclerosis	8.53e-05	0.000676	CcSEcCtD
Zalcitabine—Infection—Methylprednisolone—multiple sclerosis	8.51e-05	0.000675	CcSEcCtD
Zalcitabine—CYP3A43—Metabolism—SRM—multiple sclerosis	8.5e-05	0.00324	CbGpPWpGaD
Zalcitabine—Shock—Triamcinolone—multiple sclerosis	8.45e-05	0.00067	CcSEcCtD
Zalcitabine—Insomnia—Prednisolone—multiple sclerosis	8.45e-05	0.000669	CcSEcCtD
Zalcitabine—Alopecia—Prednisone—multiple sclerosis	8.44e-05	0.000669	CcSEcCtD
Zalcitabine—Shock—Methylprednisolone—multiple sclerosis	8.43e-05	0.000668	CcSEcCtD
Zalcitabine—Loss of consciousness—Betamethasone—multiple sclerosis	8.39e-05	0.000665	CcSEcCtD
Zalcitabine—Loss of consciousness—Dexamethasone—multiple sclerosis	8.39e-05	0.000665	CcSEcCtD
Zalcitabine—Epistaxis—Methotrexate—multiple sclerosis	8.39e-05	0.000665	CcSEcCtD
Zalcitabine—Hypersensitivity—Mitoxantrone—multiple sclerosis	8.39e-05	0.000665	CcSEcCtD
Zalcitabine—Tachycardia—Triamcinolone—multiple sclerosis	8.38e-05	0.000664	CcSEcCtD
Zalcitabine—Tachycardia—Methylprednisolone—multiple sclerosis	8.36e-05	0.000663	CcSEcCtD
Zalcitabine—Skin disorder—Methylprednisolone—multiple sclerosis	8.32e-05	0.00066	CcSEcCtD
Zalcitabine—Hyperhidrosis—Triamcinolone—multiple sclerosis	8.3e-05	0.000658	CcSEcCtD
Zalcitabine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	8.28e-05	0.000657	CcSEcCtD
Zalcitabine—Convulsion—Dexamethasone—multiple sclerosis	8.27e-05	0.000656	CcSEcCtD
Zalcitabine—Convulsion—Betamethasone—multiple sclerosis	8.27e-05	0.000656	CcSEcCtD
Zalcitabine—Hypertension—Dexamethasone—multiple sclerosis	8.24e-05	0.000653	CcSEcCtD
Zalcitabine—Hypertension—Betamethasone—multiple sclerosis	8.24e-05	0.000653	CcSEcCtD
Zalcitabine—Asthenia—Mitoxantrone—multiple sclerosis	8.17e-05	0.000647	CcSEcCtD
Zalcitabine—Myalgia—Dexamethasone—multiple sclerosis	8.13e-05	0.000644	CcSEcCtD
Zalcitabine—Myalgia—Betamethasone—multiple sclerosis	8.13e-05	0.000644	CcSEcCtD
Zalcitabine—Anxiety—Betamethasone—multiple sclerosis	8.1e-05	0.000642	CcSEcCtD
Zalcitabine—Anxiety—Dexamethasone—multiple sclerosis	8.1e-05	0.000642	CcSEcCtD
Zalcitabine—Discomfort—Dexamethasone—multiple sclerosis	8.03e-05	0.000637	CcSEcCtD
Zalcitabine—Discomfort—Betamethasone—multiple sclerosis	8.03e-05	0.000637	CcSEcCtD
Zalcitabine—Pain—Prednisolone—multiple sclerosis	7.99e-05	0.000633	CcSEcCtD
Zalcitabine—Hepatitis—Methotrexate—multiple sclerosis	7.98e-05	0.000633	CcSEcCtD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—MYC—multiple sclerosis	7.98e-05	0.00304	CbGpPWpGaD
Zalcitabine—Pharyngitis—Methotrexate—multiple sclerosis	7.92e-05	0.000628	CcSEcCtD
Zalcitabine—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	7.89e-05	0.003	CbGpPWpGaD
Zalcitabine—CYP3A43—Biological oxidations—POMC—multiple sclerosis	7.88e-05	0.003	CbGpPWpGaD
Zalcitabine—Vision blurred—Prednisone—multiple sclerosis	7.84e-05	0.000621	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	7.82e-05	0.00062	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	7.81e-05	0.000619	CcSEcCtD
Zalcitabine—Oedema—Dexamethasone—multiple sclerosis	7.79e-05	0.000618	CcSEcCtD
Zalcitabine—Oedema—Betamethasone—multiple sclerosis	7.79e-05	0.000618	CcSEcCtD
Zalcitabine—Diarrhoea—Mitoxantrone—multiple sclerosis	7.79e-05	0.000617	CcSEcCtD
Zalcitabine—Insomnia—Triamcinolone—multiple sclerosis	7.77e-05	0.000616	CcSEcCtD
Zalcitabine—Insomnia—Methylprednisolone—multiple sclerosis	7.75e-05	0.000614	CcSEcCtD
Zalcitabine—Infection—Dexamethasone—multiple sclerosis	7.74e-05	0.000614	CcSEcCtD
Zalcitabine—Infection—Betamethasone—multiple sclerosis	7.74e-05	0.000614	CcSEcCtD
Zalcitabine—Ill-defined disorder—Prednisone—multiple sclerosis	7.71e-05	0.000611	CcSEcCtD
Zalcitabine—Feeling abnormal—Prednisolone—multiple sclerosis	7.69e-05	0.00061	CcSEcCtD
Zalcitabine—Visual impairment—Methotrexate—multiple sclerosis	7.69e-05	0.00061	CcSEcCtD
Zalcitabine—Anaemia—Prednisone—multiple sclerosis	7.68e-05	0.000609	CcSEcCtD
Zalcitabine—Shock—Betamethasone—multiple sclerosis	7.67e-05	0.000608	CcSEcCtD
Zalcitabine—Shock—Dexamethasone—multiple sclerosis	7.67e-05	0.000608	CcSEcCtD
Zalcitabine—Dyspnoea—Triamcinolone—multiple sclerosis	7.66e-05	0.000607	CcSEcCtD
Zalcitabine—Agitation—Prednisone—multiple sclerosis	7.64e-05	0.000606	CcSEcCtD
Zalcitabine—Thrombocytopenia—Betamethasone—multiple sclerosis	7.63e-05	0.000605	CcSEcCtD
Zalcitabine—Thrombocytopenia—Dexamethasone—multiple sclerosis	7.63e-05	0.000605	CcSEcCtD
Zalcitabine—Tachycardia—Dexamethasone—multiple sclerosis	7.6e-05	0.000603	CcSEcCtD
Zalcitabine—Tachycardia—Betamethasone—multiple sclerosis	7.6e-05	0.000603	CcSEcCtD
Zalcitabine—Dyspepsia—Triamcinolone—multiple sclerosis	7.56e-05	0.000599	CcSEcCtD
Zalcitabine—Dyspepsia—Methylprednisolone—multiple sclerosis	7.54e-05	0.000598	CcSEcCtD
Zalcitabine—Hyperhidrosis—Betamethasone—multiple sclerosis	7.53e-05	0.000597	CcSEcCtD
Zalcitabine—Hyperhidrosis—Dexamethasone—multiple sclerosis	7.53e-05	0.000597	CcSEcCtD
Zalcitabine—Malaise—Prednisone—multiple sclerosis	7.5e-05	0.000594	CcSEcCtD
Zalcitabine—Vertigo—Prednisone—multiple sclerosis	7.47e-05	0.000592	CcSEcCtD
Zalcitabine—Eye disorder—Methotrexate—multiple sclerosis	7.46e-05	0.000591	CcSEcCtD
Zalcitabine—Syncope—Prednisone—multiple sclerosis	7.46e-05	0.000591	CcSEcCtD
Zalcitabine—Tinnitus—Methotrexate—multiple sclerosis	7.44e-05	0.00059	CcSEcCtD
Zalcitabine—Anorexia—Betamethasone—multiple sclerosis	7.43e-05	0.000589	CcSEcCtD
Zalcitabine—Anorexia—Dexamethasone—multiple sclerosis	7.43e-05	0.000589	CcSEcCtD
Zalcitabine—Urticaria—Prednisolone—multiple sclerosis	7.42e-05	0.000588	CcSEcCtD
Zalcitabine—Fatigue—Triamcinolone—multiple sclerosis	7.4e-05	0.000587	CcSEcCtD
Zalcitabine—Fatigue—Methylprednisolone—multiple sclerosis	7.39e-05	0.000586	CcSEcCtD
Zalcitabine—CYP3A7—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.37e-05	0.00281	CbGpPWpGaD
Zalcitabine—Pain—Triamcinolone—multiple sclerosis	7.34e-05	0.000582	CcSEcCtD
Zalcitabine—Loss of consciousness—Prednisone—multiple sclerosis	7.31e-05	0.000579	CcSEcCtD
Zalcitabine—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	7.25e-05	0.00276	CbGpPWpGaD
Zalcitabine—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	7.25e-05	0.00276	CbGpPWpGaD
Zalcitabine—Vomiting—Mitoxantrone—multiple sclerosis	7.24e-05	0.000574	CcSEcCtD
Zalcitabine—Convulsion—Prednisone—multiple sclerosis	7.2e-05	0.000571	CcSEcCtD
Zalcitabine—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	7.19e-05	0.00274	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	7.19e-05	0.00274	CbGpPWpGaD
Zalcitabine—Hypertension—Prednisone—multiple sclerosis	7.18e-05	0.000569	CcSEcCtD
Zalcitabine—Rash—Mitoxantrone—multiple sclerosis	7.18e-05	0.000569	CcSEcCtD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	7.17e-05	0.00273	CbGpPWpGaD
Zalcitabine—Dermatitis—Mitoxantrone—multiple sclerosis	7.17e-05	0.000568	CcSEcCtD
Zalcitabine—Chills—Methotrexate—multiple sclerosis	7.16e-05	0.000568	CcSEcCtD
Zalcitabine—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	7.15e-05	0.00272	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	7.15e-05	0.00272	CbGpPWpGaD
Zalcitabine—Headache—Mitoxantrone—multiple sclerosis	7.13e-05	0.000565	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	7.1e-05	0.000563	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	7.1e-05	0.000563	CcSEcCtD
Zalcitabine—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	7.09e-05	0.0027	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	7.09e-05	0.0027	CbGpPWpGaD
Zalcitabine—Arthralgia—Prednisone—multiple sclerosis	7.08e-05	0.000561	CcSEcCtD
Zalcitabine—Myalgia—Prednisone—multiple sclerosis	7.08e-05	0.000561	CcSEcCtD
Zalcitabine—Feeling abnormal—Triamcinolone—multiple sclerosis	7.08e-05	0.000561	CcSEcCtD
Zalcitabine—Feeling abnormal—Methylprednisolone—multiple sclerosis	7.06e-05	0.00056	CcSEcCtD
Zalcitabine—Anxiety—Prednisone—multiple sclerosis	7.05e-05	0.000559	CcSEcCtD
Zalcitabine—Alopecia—Methotrexate—multiple sclerosis	7.05e-05	0.000559	CcSEcCtD
Zalcitabine—Insomnia—Dexamethasone—multiple sclerosis	7.05e-05	0.000559	CcSEcCtD
Zalcitabine—Insomnia—Betamethasone—multiple sclerosis	7.05e-05	0.000559	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	7.01e-05	0.000555	CcSEcCtD
Zalcitabine—Discomfort—Prednisone—multiple sclerosis	6.99e-05	0.000554	CcSEcCtD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	6.92e-05	0.00263	CbGpPWpGaD
Zalcitabine—Hypersensitivity—Prednisolone—multiple sclerosis	6.88e-05	0.000545	CcSEcCtD
Zalcitabine—Dyspepsia—Betamethasone—multiple sclerosis	6.86e-05	0.000544	CcSEcCtD
Zalcitabine—Dyspepsia—Dexamethasone—multiple sclerosis	6.86e-05	0.000544	CcSEcCtD
Zalcitabine—Urticaria—Triamcinolone—multiple sclerosis	6.82e-05	0.000541	CcSEcCtD
Zalcitabine—Urticaria—Methylprednisolone—multiple sclerosis	6.81e-05	0.00054	CcSEcCtD
Zalcitabine—Dysgeusia—Methotrexate—multiple sclerosis	6.8e-05	0.000539	CcSEcCtD
Zalcitabine—Body temperature increased—Triamcinolone—multiple sclerosis	6.79e-05	0.000538	CcSEcCtD
Zalcitabine—Oedema—Prednisone—multiple sclerosis	6.79e-05	0.000538	CcSEcCtD
Zalcitabine—Abdominal pain—Methylprednisolone—multiple sclerosis	6.77e-05	0.000537	CcSEcCtD
Zalcitabine—Decreased appetite—Betamethasone—multiple sclerosis	6.77e-05	0.000537	CcSEcCtD
Zalcitabine—Decreased appetite—Dexamethasone—multiple sclerosis	6.77e-05	0.000537	CcSEcCtD
Zalcitabine—Infection—Prednisone—multiple sclerosis	6.74e-05	0.000534	CcSEcCtD
Zalcitabine—Back pain—Methotrexate—multiple sclerosis	6.72e-05	0.000533	CcSEcCtD
Zalcitabine—Fatigue—Dexamethasone—multiple sclerosis	6.72e-05	0.000532	CcSEcCtD
Zalcitabine—Fatigue—Betamethasone—multiple sclerosis	6.72e-05	0.000532	CcSEcCtD
Zalcitabine—Shock—Prednisone—multiple sclerosis	6.68e-05	0.000529	CcSEcCtD
Zalcitabine—Pain—Betamethasone—multiple sclerosis	6.66e-05	0.000528	CcSEcCtD
Zalcitabine—Pain—Dexamethasone—multiple sclerosis	6.66e-05	0.000528	CcSEcCtD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	6.64e-05	0.00253	CbGpPWpGaD
Zalcitabine—Tachycardia—Prednisone—multiple sclerosis	6.62e-05	0.000525	CcSEcCtD
Zalcitabine—Skin disorder—Prednisone—multiple sclerosis	6.59e-05	0.000522	CcSEcCtD
Zalcitabine—Hyperhidrosis—Prednisone—multiple sclerosis	6.56e-05	0.00052	CcSEcCtD
Zalcitabine—Vision blurred—Methotrexate—multiple sclerosis	6.55e-05	0.000519	CcSEcCtD
Zalcitabine—Anorexia—Prednisone—multiple sclerosis	6.47e-05	0.000513	CcSEcCtD
Zalcitabine—Ill-defined disorder—Methotrexate—multiple sclerosis	6.45e-05	0.000511	CcSEcCtD
Zalcitabine—Anaemia—Methotrexate—multiple sclerosis	6.42e-05	0.000509	CcSEcCtD
Zalcitabine—Feeling abnormal—Dexamethasone—multiple sclerosis	6.42e-05	0.000509	CcSEcCtD
Zalcitabine—Feeling abnormal—Betamethasone—multiple sclerosis	6.42e-05	0.000509	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	6.37e-05	0.000505	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Betamethasone—multiple sclerosis	6.37e-05	0.000505	CcSEcCtD
Zalcitabine—Hypersensitivity—Triamcinolone—multiple sclerosis	6.33e-05	0.000501	CcSEcCtD
Zalcitabine—Hypersensitivity—Methylprednisolone—multiple sclerosis	6.31e-05	0.0005	CcSEcCtD
Zalcitabine—Malaise—Methotrexate—multiple sclerosis	6.27e-05	0.000497	CcSEcCtD
Zalcitabine—Vertigo—Methotrexate—multiple sclerosis	6.24e-05	0.000495	CcSEcCtD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	6.23e-05	0.00237	CbGpPWpGaD
Zalcitabine—Leukopenia—Methotrexate—multiple sclerosis	6.22e-05	0.000493	CcSEcCtD
Zalcitabine—Urticaria—Betamethasone—multiple sclerosis	6.19e-05	0.000491	CcSEcCtD
Zalcitabine—Urticaria—Dexamethasone—multiple sclerosis	6.19e-05	0.000491	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	6.18e-05	0.00049	CcSEcCtD
Zalcitabine—Dizziness—Prednisolone—multiple sclerosis	6.17e-05	0.000489	CcSEcCtD
Zalcitabine—Asthenia—Triamcinolone—multiple sclerosis	6.16e-05	0.000488	CcSEcCtD
Zalcitabine—Body temperature increased—Dexamethasone—multiple sclerosis	6.16e-05	0.000488	CcSEcCtD
Zalcitabine—Abdominal pain—Dexamethasone—multiple sclerosis	6.16e-05	0.000488	CcSEcCtD
Zalcitabine—Abdominal pain—Betamethasone—multiple sclerosis	6.16e-05	0.000488	CcSEcCtD
Zalcitabine—Body temperature increased—Betamethasone—multiple sclerosis	6.16e-05	0.000488	CcSEcCtD
Zalcitabine—Asthenia—Methylprednisolone—multiple sclerosis	6.15e-05	0.000487	CcSEcCtD
Zalcitabine—Insomnia—Prednisone—multiple sclerosis	6.14e-05	0.000486	CcSEcCtD
Zalcitabine—DCK—Metabolism—CYP27B1—multiple sclerosis	6.08e-05	0.00232	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—CYP24A1—multiple sclerosis	6.08e-05	0.00232	CbGpPWpGaD
Zalcitabine—Pruritus—Triamcinolone—multiple sclerosis	6.08e-05	0.000482	CcSEcCtD
Zalcitabine—Cough—Methotrexate—multiple sclerosis	6.06e-05	0.000481	CcSEcCtD
Zalcitabine—Pruritus—Methylprednisolone—multiple sclerosis	6.06e-05	0.00048	CcSEcCtD
Zalcitabine—Convulsion—Methotrexate—multiple sclerosis	6.02e-05	0.000477	CcSEcCtD
Zalcitabine—CYP3A43—Metabolism—CYP27B1—multiple sclerosis	5.99e-05	0.00228	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—CYP24A1—multiple sclerosis	5.99e-05	0.00228	CbGpPWpGaD
Zalcitabine—CYP3A7—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.98e-05	0.00227	CbGpPWpGaD
Zalcitabine—Dyspepsia—Prednisone—multiple sclerosis	5.97e-05	0.000473	CcSEcCtD
Zalcitabine—Arthralgia—Methotrexate—multiple sclerosis	5.92e-05	0.000469	CcSEcCtD
Zalcitabine—Myalgia—Methotrexate—multiple sclerosis	5.92e-05	0.000469	CcSEcCtD
Zalcitabine—Decreased appetite—Prednisone—multiple sclerosis	5.9e-05	0.000468	CcSEcCtD
Zalcitabine—Rash—Prednisolone—multiple sclerosis	5.89e-05	0.000467	CcSEcCtD
Zalcitabine—Dermatitis—Prednisolone—multiple sclerosis	5.88e-05	0.000466	CcSEcCtD
Zalcitabine—Diarrhoea—Methylprednisolone—multiple sclerosis	5.86e-05	0.000465	CcSEcCtD
Zalcitabine—Fatigue—Prednisone—multiple sclerosis	5.85e-05	0.000464	CcSEcCtD
Zalcitabine—Headache—Prednisolone—multiple sclerosis	5.85e-05	0.000464	CcSEcCtD
Zalcitabine—Discomfort—Methotrexate—multiple sclerosis	5.84e-05	0.000463	CcSEcCtD
Zalcitabine—Confusional state—Methotrexate—multiple sclerosis	5.72e-05	0.000453	CcSEcCtD
Zalcitabine—Dizziness—Triamcinolone—multiple sclerosis	5.68e-05	0.00045	CcSEcCtD
Zalcitabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	5.68e-05	0.00216	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—AQP4—multiple sclerosis	5.67e-05	0.00216	CbGpPWpGaD
Zalcitabine—Dizziness—Methylprednisolone—multiple sclerosis	5.67e-05	0.000449	CcSEcCtD
Zalcitabine—Infection—Methotrexate—multiple sclerosis	5.63e-05	0.000447	CcSEcCtD
Zalcitabine—Feeling abnormal—Prednisone—multiple sclerosis	5.59e-05	0.000443	CcSEcCtD
Zalcitabine—Asthenia—Betamethasone—multiple sclerosis	5.59e-05	0.000443	CcSEcCtD
Zalcitabine—Asthenia—Dexamethasone—multiple sclerosis	5.59e-05	0.000443	CcSEcCtD
Zalcitabine—DCK—Metabolism—GPC5—multiple sclerosis	5.56e-05	0.00212	CbGpPWpGaD
Zalcitabine—Thrombocytopenia—Methotrexate—multiple sclerosis	5.55e-05	0.00044	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Prednisone—multiple sclerosis	5.55e-05	0.00044	CcSEcCtD
Zalcitabine—Pruritus—Betamethasone—multiple sclerosis	5.51e-05	0.000437	CcSEcCtD
Zalcitabine—Pruritus—Dexamethasone—multiple sclerosis	5.51e-05	0.000437	CcSEcCtD
Zalcitabine—Skin disorder—Methotrexate—multiple sclerosis	5.51e-05	0.000437	CcSEcCtD
Zalcitabine—Hyperhidrosis—Methotrexate—multiple sclerosis	5.48e-05	0.000435	CcSEcCtD
Zalcitabine—CYP3A43—Metabolism—GPC5—multiple sclerosis	5.48e-05	0.00209	CbGpPWpGaD
Zalcitabine—Vomiting—Triamcinolone—multiple sclerosis	5.46e-05	0.000433	CcSEcCtD
Zalcitabine—Vomiting—Methylprednisolone—multiple sclerosis	5.45e-05	0.000432	CcSEcCtD
Zalcitabine—Rash—Triamcinolone—multiple sclerosis	5.41e-05	0.000429	CcSEcCtD
Zalcitabine—Dermatitis—Triamcinolone—multiple sclerosis	5.41e-05	0.000429	CcSEcCtD
Zalcitabine—Anorexia—Methotrexate—multiple sclerosis	5.41e-05	0.000428	CcSEcCtD
Zalcitabine—Rash—Methylprednisolone—multiple sclerosis	5.4e-05	0.000428	CcSEcCtD
Zalcitabine—Dermatitis—Methylprednisolone—multiple sclerosis	5.4e-05	0.000428	CcSEcCtD
Zalcitabine—Urticaria—Prednisone—multiple sclerosis	5.39e-05	0.000427	CcSEcCtD
Zalcitabine—Headache—Triamcinolone—multiple sclerosis	5.38e-05	0.000426	CcSEcCtD
Zalcitabine—Headache—Methylprednisolone—multiple sclerosis	5.37e-05	0.000425	CcSEcCtD
Zalcitabine—Body temperature increased—Prednisone—multiple sclerosis	5.36e-05	0.000425	CcSEcCtD
Zalcitabine—Abdominal pain—Prednisone—multiple sclerosis	5.36e-05	0.000425	CcSEcCtD
Zalcitabine—Diarrhoea—Betamethasone—multiple sclerosis	5.33e-05	0.000423	CcSEcCtD
Zalcitabine—Diarrhoea—Dexamethasone—multiple sclerosis	5.33e-05	0.000423	CcSEcCtD
Zalcitabine—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.33e-05	0.00203	CbGpPWpGaD
Zalcitabine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	5.17e-05	0.00041	CcSEcCtD
Zalcitabine—Dizziness—Betamethasone—multiple sclerosis	5.15e-05	0.000408	CcSEcCtD
Zalcitabine—Dizziness—Dexamethasone—multiple sclerosis	5.15e-05	0.000408	CcSEcCtD
Zalcitabine—Insomnia—Methotrexate—multiple sclerosis	5.13e-05	0.000407	CcSEcCtD
Zalcitabine—Dyspnoea—Methotrexate—multiple sclerosis	5.06e-05	0.000401	CcSEcCtD
Zalcitabine—Somnolence—Methotrexate—multiple sclerosis	5.04e-05	0.0004	CcSEcCtD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	5.03e-05	0.00191	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	5.01e-05	0.00191	CbGpPWpGaD
Zalcitabine—Hypersensitivity—Prednisone—multiple sclerosis	5e-05	0.000396	CcSEcCtD
Zalcitabine—Dyspepsia—Methotrexate—multiple sclerosis	4.99e-05	0.000396	CcSEcCtD
Zalcitabine—Vomiting—Dexamethasone—multiple sclerosis	4.95e-05	0.000393	CcSEcCtD
Zalcitabine—Vomiting—Betamethasone—multiple sclerosis	4.95e-05	0.000393	CcSEcCtD
Zalcitabine—Decreased appetite—Methotrexate—multiple sclerosis	4.93e-05	0.000391	CcSEcCtD
Zalcitabine—Rash—Betamethasone—multiple sclerosis	4.91e-05	0.000389	CcSEcCtD
Zalcitabine—Rash—Dexamethasone—multiple sclerosis	4.91e-05	0.000389	CcSEcCtD
Zalcitabine—Dermatitis—Dexamethasone—multiple sclerosis	4.91e-05	0.000389	CcSEcCtD
Zalcitabine—Dermatitis—Betamethasone—multiple sclerosis	4.91e-05	0.000389	CcSEcCtD
Zalcitabine—Fatigue—Methotrexate—multiple sclerosis	4.89e-05	0.000388	CcSEcCtD
Zalcitabine—Headache—Betamethasone—multiple sclerosis	4.88e-05	0.000387	CcSEcCtD
Zalcitabine—Headache—Dexamethasone—multiple sclerosis	4.88e-05	0.000387	CcSEcCtD
Zalcitabine—Asthenia—Prednisone—multiple sclerosis	4.87e-05	0.000386	CcSEcCtD
Zalcitabine—Pain—Methotrexate—multiple sclerosis	4.85e-05	0.000384	CcSEcCtD
Zalcitabine—Pruritus—Prednisone—multiple sclerosis	4.8e-05	0.000381	CcSEcCtD
Zalcitabine—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	4.74e-05	0.00181	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	4.74e-05	0.00181	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	4.68e-05	0.00178	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	4.68e-05	0.00178	CbGpPWpGaD
Zalcitabine—Feeling abnormal—Methotrexate—multiple sclerosis	4.67e-05	0.00037	CcSEcCtD
Zalcitabine—Diarrhoea—Prednisone—multiple sclerosis	4.64e-05	0.000368	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Methotrexate—multiple sclerosis	4.64e-05	0.000368	CcSEcCtD
Zalcitabine—DCK—Metabolism—RRM1—multiple sclerosis	4.61e-05	0.00176	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	4.57e-05	0.00174	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—RRM1—multiple sclerosis	4.54e-05	0.00173	CbGpPWpGaD
Zalcitabine—Urticaria—Methotrexate—multiple sclerosis	4.5e-05	0.000357	CcSEcCtD
Zalcitabine—Dizziness—Prednisone—multiple sclerosis	4.49e-05	0.000356	CcSEcCtD
Zalcitabine—Body temperature increased—Methotrexate—multiple sclerosis	4.48e-05	0.000355	CcSEcCtD
Zalcitabine—Abdominal pain—Methotrexate—multiple sclerosis	4.48e-05	0.000355	CcSEcCtD
Zalcitabine—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.32e-05	0.00164	CbGpPWpGaD
Zalcitabine—Vomiting—Prednisone—multiple sclerosis	4.31e-05	0.000342	CcSEcCtD
Zalcitabine—Rash—Prednisone—multiple sclerosis	4.28e-05	0.000339	CcSEcCtD
Zalcitabine—Dermatitis—Prednisone—multiple sclerosis	4.27e-05	0.000339	CcSEcCtD
Zalcitabine—Headache—Prednisone—multiple sclerosis	4.25e-05	0.000337	CcSEcCtD
Zalcitabine—Hypersensitivity—Methotrexate—multiple sclerosis	4.18e-05	0.000331	CcSEcCtD
Zalcitabine—Asthenia—Methotrexate—multiple sclerosis	4.07e-05	0.000323	CcSEcCtD
Zalcitabine—Pruritus—Methotrexate—multiple sclerosis	4.01e-05	0.000318	CcSEcCtD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.98e-05	0.00151	CbGpPWpGaD
Zalcitabine—Diarrhoea—Methotrexate—multiple sclerosis	3.88e-05	0.000308	CcSEcCtD
Zalcitabine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.79e-05	0.00144	CbGpPWpGaD
Zalcitabine—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.76e-05	0.00143	CbGpPWpGaD
Zalcitabine—Dizziness—Methotrexate—multiple sclerosis	3.75e-05	0.000297	CcSEcCtD
Zalcitabine—Vomiting—Methotrexate—multiple sclerosis	3.61e-05	0.000286	CcSEcCtD
Zalcitabine—Rash—Methotrexate—multiple sclerosis	3.58e-05	0.000283	CcSEcCtD
Zalcitabine—Dermatitis—Methotrexate—multiple sclerosis	3.57e-05	0.000283	CcSEcCtD
Zalcitabine—Headache—Methotrexate—multiple sclerosis	3.55e-05	0.000282	CcSEcCtD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—ALB—multiple sclerosis	3.55e-05	0.00135	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.52e-05	0.00134	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—SRM—multiple sclerosis	3.43e-05	0.0013	CbGpPWpGaD
Zalcitabine—CYP3A7—Biological oxidations—POMC—multiple sclerosis	3.17e-05	0.00121	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.17e-05	0.00121	CbGpPWpGaD
Zalcitabine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.07e-05	0.00117	CbGpPWpGaD
Zalcitabine—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.05e-05	0.00116	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	2.76e-05	0.00105	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	2.76e-05	0.00105	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—BCHE—multiple sclerosis	2.65e-05	0.00101	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—BCHE—multiple sclerosis	2.61e-05	0.000993	CbGpPWpGaD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—ALB—multiple sclerosis	2.49e-05	0.000948	CbGpPWpGaD
Zalcitabine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	2.48e-05	0.000943	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—SRM—multiple sclerosis	2.48e-05	0.000943	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—CYP27B1—multiple sclerosis	2.41e-05	0.000919	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—CYP24A1—multiple sclerosis	2.41e-05	0.000919	CbGpPWpGaD
Zalcitabine—CYP3A5—Biological oxidations—POMC—multiple sclerosis	2.29e-05	0.000873	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—GPC5—multiple sclerosis	2.21e-05	0.00084	CbGpPWpGaD
Zalcitabine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.01e-05	0.000764	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—RRM1—multiple sclerosis	1.83e-05	0.000696	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.8e-05	0.000687	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—SRM—multiple sclerosis	1.76e-05	0.00067	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—SRM—multiple sclerosis	1.75e-05	0.000664	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	1.74e-05	0.000664	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	1.74e-05	0.000664	CbGpPWpGaD
Zalcitabine—CYP2D6—Biological oxidations—POMC—multiple sclerosis	1.63e-05	0.000621	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—POMC—multiple sclerosis	1.62e-05	0.000616	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—GPC5—multiple sclerosis	1.6e-05	0.000607	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—APOE—multiple sclerosis	1.59e-05	0.000606	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—APOE—multiple sclerosis	1.57e-05	0.000597	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—POMC—multiple sclerosis	1.37e-05	0.000521	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—POMC—multiple sclerosis	1.35e-05	0.000513	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—RRM1—multiple sclerosis	1.32e-05	0.000503	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.27e-05	0.000482	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—ALB—multiple sclerosis	1.25e-05	0.000475	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	1.24e-05	0.000472	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	1.24e-05	0.000472	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	1.23e-05	0.000468	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	1.23e-05	0.000468	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—ALB—multiple sclerosis	1.23e-05	0.000468	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.2e-05	0.000458	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—SRM—multiple sclerosis	1.15e-05	0.000438	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.13e-05	0.000432	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.12e-05	0.000428	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.07e-05	0.000406	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—BCHE—multiple sclerosis	1.05e-05	0.0004	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—RRM1—multiple sclerosis	9.4e-06	0.000358	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—RRM1—multiple sclerosis	9.32e-06	0.000355	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	8.11e-06	0.000309	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	8.11e-06	0.000309	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—BCHE—multiple sclerosis	7.59e-06	0.000289	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—GPC5—multiple sclerosis	7.42e-06	0.000282	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.23e-06	0.000275	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—APOE—multiple sclerosis	6.32e-06	0.000241	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.21e-06	0.000236	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—RRM1—multiple sclerosis	6.15e-06	0.000234	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.66e-06	0.000216	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—POMC—multiple sclerosis	5.43e-06	0.000207	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—BCHE—multiple sclerosis	5.4e-06	0.000206	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—BCHE—multiple sclerosis	5.35e-06	0.000204	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—ALB—multiple sclerosis	4.95e-06	0.000188	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—APOE—multiple sclerosis	4.57e-06	0.000174	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—POMC—multiple sclerosis	3.92e-06	0.000149	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—ALB—multiple sclerosis	3.58e-06	0.000136	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—BCHE—multiple sclerosis	3.53e-06	0.000134	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—APOE—multiple sclerosis	3.25e-06	0.000124	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—APOE—multiple sclerosis	3.22e-06	0.000123	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—POMC—multiple sclerosis	2.79e-06	0.000106	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—POMC—multiple sclerosis	2.77e-06	0.000105	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—ALB—multiple sclerosis	2.54e-06	9.68e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—ALB—multiple sclerosis	2.52e-06	9.6e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—APOE—multiple sclerosis	2.12e-06	8.08e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—POMC—multiple sclerosis	1.82e-06	6.94e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—ALB—multiple sclerosis	1.66e-06	6.33e-05	CbGpPWpGaD
